INT157832

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.77
First Reported 2005
Last Reported 2009
Negated 0
Speculated 0
Reported most in Body
Documents 2
Total Number 4
Disease Relevance 2.04
Pain Relevance 0.08

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

aging (Aqp2) plasma membrane (Aqp2) protein complex (Aqp2)
transmembrane transport (Aqp2) lysosome (Aqp2) cytoplasm (Aqp2)
Anatomy Link Frequency
urine 3
inner medulla 1
Aqp2 (Rattus norvegicus)
Pain Link Frequency Relevance Heat
medulla 3 54.40 Quite High
anesthesia 10 10.00 Low Low
isoflurane 12 5.00 Very Low Very Low Very Low
antagonist 9 5.00 Very Low Very Low Very Low
fibrosis 3 5.00 Very Low Very Low Very Low
bradykinin 3 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Chronic Renal Failure 372 81.48 Quite High
Uremia 12 36.44 Quite Low
Congenital Anomalies 3 28.72 Quite Low
Hypertrophy 33 5.00 Very Low Very Low Very Low
Natriuresis 7 5.00 Very Low Very Low Very Low
Fibrosis 3 5.00 Very Low Very Low Very Low
Disorders Of Creatine Metabolism 3 5.00 Very Low Very Low Very Low
Hypercalcemia 3 5.00 Very Low Very Low Very Low
Injury 3 5.00 Very Low Very Low Very Low
Bartter Syndrome 3 5.00 Very Low Very Low Very Low

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Interestingly, in a parallel study, we found that treatment with the AT1 receptor blocker candesartan in NaCl-restricted normal rats prevented the increase of the expression of inner medullary AQP2 and phosphorylated-AQP2 (AQP2 phosphorylated in the PKA-phosphorylation consensus site Ser-256) and the increase of urine concentration in response to the long-term dDAVP treatment (25).
Phosphorylation (phosphorylated) of AQP2 in urine
1) Confidence 0.77 Published 2005 Journal Journal of Korean Medical Science Section Body Doc Link PMC2808601 Disease Relevance 0.68 Pain Relevance 0.03
Interestingly, in a parallel study, we found that treatment with the AT1 receptor blocker candesartan in NaCl-restricted normal rats prevented the increase of the expression of inner medullary AQP2 and phosphorylated-AQP2 (AQP2 phosphorylated in the PKA-phosphorylation consensus site Ser-256) and the increase of urine concentration in response to the long-term dDAVP treatment (25).
Phosphorylation (phosphorylated) of AQP2 in urine
2) Confidence 0.66 Published 2005 Journal Journal of Korean Medical Science Section Body Doc Link PMC2808601 Disease Relevance 0.68 Pain Relevance 0.03
RESULTS: Polyuria and increased natriuresis were seen 6 h after LPS injection alongside downregulation of both AQP2 and S256-phosphorylated AQP2 in CTX/OSOM and ISOM but not in inner medulla (IM).
Phosphorylation (phosphorylated) of AQP2 in inner medulla
3) Confidence 0.61 Published 2009 Journal Nephrol. Dial. Transplant. Section Body Doc Link 19193739 Disease Relevance 0 Pain Relevance 0
Interestingly, in a parallel study, we found that treatment with the AT1 receptor blocker candesartan in NaCl-restricted normal rats prevented the increase of the expression of inner medullary AQP2 and phosphorylated-AQP2 (AQP2 phosphorylated in the PKA-phosphorylation consensus site Ser-256) and the increase of urine concentration in response to the long-term dDAVP treatment (25).
Phosphorylation (phosphorylated) of AQP2 in urine
4) Confidence 0.59 Published 2005 Journal Journal of Korean Medical Science Section Body Doc Link PMC2808601 Disease Relevance 0.68 Pain Relevance 0.03

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox